CGT

CGTBiologicstalePersonGen BioTherapeutics (Suzh…Phase 2

anti-CD19 CAR-T cells (PCAR-019, PCAR-019 (anti-CD19 CAR-T cells))

Acute Lymphocytic Leukemia; Chronic Lymphocytic Leukemia · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+4

효능 ORR 94%임상시험 1상태 ACTIVE

CGTBiologicstaleShanghai Cell Therapy Research …Phase 2

PD-1 antibody expressing mesoCAR-T cells (PD-1 antibody expressing mesoCAR-T cells)

Advanced Solid Tumor · PD-1

#PD-1#CGT#Phase2#세포유전치료#CAR-T+3

임상시험 1상태 ACTIVE

CGTBiologicstaleNingbo Cancer HospitalPhase 2

PD-1 antibody expressing mesothelin specific CAR-T cells (PD-1 antibody expressing mesothelin specific CAR-T cells)

Solid Tumor, Adult; Advanced Cancer · PD-1

#PD-1#CGT#Phase2#세포유전치료#CAR-T+5

임상시험 1상태 ACTIVE

CGTBiologicstalejiuwei cuiPhase 1

PD-1-M1-NK Cells (PD-1-M1-NK Cells)

Advanced Gastric or Colorectal Cancer · PD-1

#PD-1#CGT#Phase1#세포유전치료#CAR-T+3

임상시험 1상태 RECRUITING

CGTBiologicstaleDaihong LiuPhase 2

PD-1Ab21-BCMA CAR-T cell immunotherapy (PD-1Ab21-BCMA CAR-T cell immunotherapy)

Multiple Myeloma · PD-1

#PD-1#CGT#Phase2#세포유전치료#CAR-T+3

임상시험 1상태 RECRUITING

CGTBiologicstaleZhejiang UniversityPhase 1

PD1-PSMA-CART cells (PD1-PSMA-CART cells)

Castrate-Resistant Prostate Cancer · PSMA

#PSMA#CGT#Phase1#세포유전치료#CAR-T+3

임상시험 1상태 ACTIVE

CGTBiologicstaleNational Cancer Institute (NCI)Phase 1

Anti-CEA TCR PBL (PG13-CEA_TCR, PG13-CEA_TCR (Anti-CEA TCR PBL))

Metastatic Cancer · CEA

#CEA#CGT#Phase1#세포유전치료#CAR-T+3

임상시험 1상태 DISCONTINUED

CGTBiologicstaleNational Cancer Institute (NCI)Phase 2

PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR, PG13-MAGE-A3 TCR9W11, PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes)

Metastatic Cancer; Metastatic Renal Cancer · Metastatic Cancer

#MetastaticCancer#CGT#Phase2#세포유전치료#CAR-T+3

임상시험 1상태 DISCONTINUED

CGTBiologicstaleStephan Grupp MD PhDPhase 1

PHOX2B PC-CAR T Cells (PHOX2B PC-CAR T Cells)

Refractory Neuroblastoma; Relapsed Neuroblastoma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4

임상시험 1상태 RECRUITING

CGTBiologicstalePrecigen, IncPhase 1

PRGN-3005 UltraCAR-T cells (PRGN-3005 UltraCAR-T cells)

Platinum-Resistant Fallopian Tube Carcinoma; Platinum-Resistant Ovarian Carcinoma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4

임상시험 1상태 RECRUITING

CGTBiologicstaleShanghai Changzheng HospitalPhase 1

BRL-302 (PSMA-UCAR T, PSMA-UCAR T (BRL-302))

Metastatic Prostate Cancer; Castration-resistant Prostate Cancer · PSMA

#PSMA#CGT#Phase1#세포유전치료#CAR-T+4

임상시험 1상태 RECRUITING

CGTBiologicstalePinze Lifetechnology Co. Ltd.Phase 1

PZ01 CAR-T cells (PZ01 CAR-T cells)

B-cell Acute Lymphoblastic Leukemia; B-cell Lymphoma · B-cell Acute Lymphoblastic Leukemia

#B-cellAcuteLymphoblasticLeukemia#CGT#Phase1#세포유전치료#CAR-T+3

임상시험 1상태 ACTIVE

CGTBiologicstaleChinese PLA General HospitalPhase 2

Pan-T booster co-expressing MSLN CAR T cell (Pan-T booster co-expressing MSLN CAR T cell)

Advanced or Metastatic Solid Tumors · Advanced or Metastatic Solid Tumors

#AdvancedorMetastaticSolidTumors#CGT#Phase2#세포유전치료#CAR-T+2

임상시험 1상태 RECRUITING

CGTBiologicstaleThe Evan FoundationPhase 1

2nd generation T cells (Patient Derived CD171 specific CAR T cells expressing EGFRt, Patient Derived CD171 specific CAR T cells expressing EGFRt (2nd generation T cells))

Neuroblastoma; Ganglioneuroblastoma · EGFR

#EGFR#CGT#Phase1#세포유전치료#CAR-T+4

임상시험 1상태 RECRUITING

CGTBiologicstaleSeattle Children's HospitalPhase 1

3rd generation T cells (Patient Derived CD171 specific CAR T cells expressing EGFRt, Patient Derived CD171 specific CAR T cells expressing EGFRt (3rd generation T cells))

Neuroblastoma; Ganglioneuroblastoma · EGFR

#EGFR#CGT#Phase1#세포유전치료#CAR-T+4

임상시험 1상태 RECRUITING

CGTBiologicstaleThe Evan FoundationPhase 1

long spacer 2nd generation T cells (Patient Derived CD171 specific CAR T cells expressing EGFRt, Patient Derived CD171 specific CAR T cells expressing EGFRt (long spacer 2nd generation T cells))

Neuroblastoma; Ganglioneuroblastoma · EGFR

#EGFR#CGT#Phase1#세포유전치료#CAR-T+4

임상시험 1상태 RECRUITING

CGTBiologicstalePell Bio-Med Technology Co., Lt…Preclinical

Pell's lentiviral-based gene-edited immune cell therapy (Pell's lentiviral-based gene-edited immune cell therapy)

Diffuse Large B Cell Lymphoma; Large B-cell Lymphoma · Diffuse Large B Cell Lymphoma

#DiffuseLargeBCellLymphoma#CGT#Preclinical#세포유전치료#CAR-T+3

임상시험 1상태 RECRUITING

CGTBiologicstaleOttawa Heart Institute Research…Phase 3

Point-of-care genetic screening with subsequent prasugrel administration to CYP2C192 carriers (Point-of-care genetic screening with subsequent prasugrel administration to CYP2C192 carriers)

Stable Coronary Artery Disease; Acute Coronary Syndrome · Stable Coronary Artery Disease

#StableCoronaryArteryDisease#CGT#Phase3#세포유전치료#CAR-T+3

임상시험 1상태 ACTIVE

CGTBiologicstaleBeijing GoBroad HospitalPhase 2

Previous stem-cell transplantation (SCT, Previous stem-cell transplantation, Previous stem-cell transplantation (SCT) donor-derived CD5 CAR T-cells)

T-Cell Acute Lymphocytic Leukemia; Acute Lymphoblastic Leukemia, in Relapse · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+5

임상시험 1상태 RECRUITING

CGTBiologicstaleNovartis PharmaceuticalsPhase 3

Previously treated CAR-T patients (Previously treated CAR-T patients)

Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program · Long Term Safety of Patients Receiving C

#LongTermSafetyofPatientsReceivin#CGT#Phase3#세포유전치료#CAR-T+2

임상시험 1상태 RECRUITING

52 / 62 페이지

← 이전 다음 →

갱신 기록 없음 · 14일 주기 · 방문 0 / 572

anti-CD19 CAR-T cells (PCAR-019, PCAR-019 (anti-CD19 CAR-T cells))

PD-1 antibody expressing mesoCAR-T cells (PD-1 antibody expressing mesoCAR-T cells)

PD-1 antibody expressing mesothelin specific CAR-T cells (PD-1 antibody expressing mesothelin specific CAR-T cells)

PD-1-M1-NK Cells (PD-1-M1-NK Cells)

PD-1Ab21-BCMA CAR-T cell immunotherapy (PD-1Ab21-BCMA CAR-T cell immunotherapy)

PD1-PSMA-CART cells (PD1-PSMA-CART cells)

Anti-CEA TCR PBL (PG13-CEA_TCR, PG13-CEA_TCR (Anti-CEA TCR PBL))

PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR, PG13-MAGE-A3 TCR9W11, PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes)

PHOX2B PC-CAR T Cells (PHOX2B PC-CAR T Cells)

PRGN-3005 UltraCAR-T cells (PRGN-3005 UltraCAR-T cells)

BRL-302 (PSMA-UCAR T, PSMA-UCAR T (BRL-302))

PZ01 CAR-T cells (PZ01 CAR-T cells)

Pan-T booster co-expressing MSLN CAR T cell (Pan-T booster co-expressing MSLN CAR T cell)

2nd generation T cells (Patient Derived CD171 specific CAR T cells expressing EGFRt, Patient Derived CD171 specific CAR T cells expressing EGFRt (2nd generation T cells))

3rd generation T cells (Patient Derived CD171 specific CAR T cells expressing EGFRt, Patient Derived CD171 specific CAR T cells expressing EGFRt (3rd generation T cells))

long spacer 2nd generation T cells (Patient Derived CD171 specific CAR T cells expressing EGFRt, Patient Derived CD171 specific CAR T cells expressing EGFRt (long spacer 2nd generation T cells))

Pell's lentiviral-based gene-edited immune cell therapy (Pell's lentiviral-based gene-edited immune cell therapy)

Point-of-care genetic screening with subsequent prasugrel administration to CYP2C19*2 carriers (Point-of-care genetic screening with subsequent prasugrel administration to CYP2C19*2 carriers)

Previous stem-cell transplantation (SCT, Previous stem-cell transplantation, Previous stem-cell transplantation (SCT) donor-derived CD5 CAR T-cells)

Previously treated CAR-T patients (Previously treated CAR-T patients)

CGT

anti-CD19 CAR-T cells (PCAR-019, PCAR-019 (anti-CD19 CAR-T cells))

PD-1 antibody expressing mesoCAR-T cells (PD-1 antibody expressing mesoCAR-T cells)

PD-1 antibody expressing mesothelin specific CAR-T cells (PD-1 antibody expressing mesothelin specific CAR-T cells)

PD-1-M1-NK Cells (PD-1-M1-NK Cells)

PD-1Ab21-BCMA CAR-T cell immunotherapy (PD-1Ab21-BCMA CAR-T cell immunotherapy)

PD1-PSMA-CART cells (PD1-PSMA-CART cells)

Anti-CEA TCR PBL (PG13-CEA_TCR, PG13-CEA_TCR (Anti-CEA TCR PBL))

PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR, PG13-MAGE-A3 TCR9W11, PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes)

PHOX2B PC-CAR T Cells (PHOX2B PC-CAR T Cells)

PRGN-3005 UltraCAR-T cells (PRGN-3005 UltraCAR-T cells)

BRL-302 (PSMA-UCAR T, PSMA-UCAR T (BRL-302))

PZ01 CAR-T cells (PZ01 CAR-T cells)

Pan-T booster co-expressing MSLN CAR T cell (Pan-T booster co-expressing MSLN CAR T cell)

2nd generation T cells (Patient Derived CD171 specific CAR T cells expressing EGFRt, Patient Derived CD171 specific CAR T cells expressing EGFRt (2nd generation T cells))

3rd generation T cells (Patient Derived CD171 specific CAR T cells expressing EGFRt, Patient Derived CD171 specific CAR T cells expressing EGFRt (3rd generation T cells))

long spacer 2nd generation T cells (Patient Derived CD171 specific CAR T cells expressing EGFRt, Patient Derived CD171 specific CAR T cells expressing EGFRt (long spacer 2nd generation T cells))

Pell's lentiviral-based gene-edited immune cell therapy (Pell's lentiviral-based gene-edited immune cell therapy)

Point-of-care genetic screening with subsequent prasugrel administration to CYP2C19*2 carriers (Point-of-care genetic screening with subsequent prasugrel administration to CYP2C19*2 carriers)

Previous stem-cell transplantation (SCT, Previous stem-cell transplantation, Previous stem-cell transplantation (SCT) donor-derived CD5 CAR T-cells)

Previously treated CAR-T patients (Previously treated CAR-T patients)

CGT

anti-CD19 CAR-T cells (PCAR-019, PCAR-019 (anti-CD19 CAR-T cells))

PD-1 antibody expressing mesoCAR-T cells (PD-1 antibody expressing mesoCAR-T cells)

PD-1 antibody expressing mesothelin specific CAR-T cells (PD-1 antibody expressing mesothelin specific CAR-T cells)

PD-1-M1-NK Cells (PD-1-M1-NK Cells)

PD-1Ab21-BCMA CAR-T cell immunotherapy (PD-1Ab21-BCMA CAR-T cell immunotherapy)

PD1-PSMA-CART cells (PD1-PSMA-CART cells)

Anti-CEA TCR PBL (PG13-CEA_TCR, PG13-CEA_TCR (Anti-CEA TCR PBL))

PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR, PG13-MAGE-A3 TCR9W11, PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes)

PHOX2B PC-CAR T Cells (PHOX2B PC-CAR T Cells)

PRGN-3005 UltraCAR-T cells (PRGN-3005 UltraCAR-T cells)

BRL-302 (PSMA-UCAR T, PSMA-UCAR T (BRL-302))

PZ01 CAR-T cells (PZ01 CAR-T cells)

Pan-T booster co-expressing MSLN CAR T cell (Pan-T booster co-expressing MSLN CAR T cell)

2nd generation T cells (Patient Derived CD171 specific CAR T cells expressing EGFRt, Patient Derived CD171 specific CAR T cells expressing EGFRt (2nd generation T cells))

3rd generation T cells (Patient Derived CD171 specific CAR T cells expressing EGFRt, Patient Derived CD171 specific CAR T cells expressing EGFRt (3rd generation T cells))

long spacer 2nd generation T cells (Patient Derived CD171 specific CAR T cells expressing EGFRt, Patient Derived CD171 specific CAR T cells expressing EGFRt (long spacer 2nd generation T cells))

Pell's lentiviral-based gene-edited immune cell therapy (Pell's lentiviral-based gene-edited immune cell therapy)

Point-of-care genetic screening with subsequent prasugrel administration to CYP2C19*2 carriers (Point-of-care genetic screening with subsequent prasugrel administration to CYP2C19*2 carriers)

Previous stem-cell transplantation (SCT, Previous stem-cell transplantation, Previous stem-cell transplantation (SCT) donor-derived CD5 CAR T-cells)

Previously treated CAR-T patients (Previously treated CAR-T patients)

Point-of-care genetic screening with subsequent prasugrel administration to CYP2C192 carriers (Point-of-care genetic screening with subsequent prasugrel administration to CYP2C192 carriers)

Point-of-care genetic screening with subsequent prasugrel administration to CYP2C192 carriers (Point-of-care genetic screening with subsequent prasugrel administration to CYP2C192 carriers)

Point-of-care genetic screening with subsequent prasugrel administration to CYP2C192 carriers (Point-of-care genetic screening with subsequent prasugrel administration to CYP2C192 carriers)